Moderna, inc. (MRNA)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Dec'17
Assets
Current assets:
Cash and cash equivalents

391

235

173

151

502

658

134

Investments

825

867

884

918

605

863

621

Accounts receivable

5

5

2

3

5

11

11

Accounts receivable from related party

1

0

5

1

0

0

1

Prepaid Expense and Other Assets, Current

23

19

26

22

25

28

12

Restricted cash

1

1

1

0

0

0

0

Total current assets

1,249

1,128

1,094

1,097

1,140

1,563

783

Investments, non-current

502

159

279

365

437

172

145

Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization

202

201

203

208

213

211

139

Operating Lease, Right-of-Use Asset

100

86

-

-

-

-

-

Restricted cash, non-current

10

10

10

11

11

11

11

Other non-current assets

1

1

2

2

2

2

4

Total assets

2,067

1,589

1,590

1,685

1,806

1,962

1,084

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

11

7

11

29

38

31

20

Accrued Liabilities, Current

55

67

60

44

42

79

72

Deferred revenue

58

63

70

83

73

109

-

Deferred revenue

-

-

-

-

-

-

96

Other current liabilities

9

5

5

4

4

3

1

Total current liabilities

134

143

147

161

159

222

191

Deferred revenue, non-current

142

138

143

139

156

165

242

Operating Lease, Liability, Noncurrent

108

93

-

-

-

-

-

Finance Lease, Liability, Noncurrent

38

38

-

-

-

-

-

Deferred lease obligation, non-current

-

-

13

11

10

10

7

Lease Financing Obligation

-

-

33

33

33

33

15

Other non-current liabilities

1

0

0

0

0

0

1

Total liabilities

426

414

339

346

360

431

459

Temporary Equity, Carrying Amount, Attributable to Parent

-

-

-

-

-

-

1,176

Stockholders’ equity:
Preferred stock, par value $0.0001; 162,000,000 shares authorized as of March 31, 2020 and December 31, 2019; no shares issued or outstanding at March 31, 2020 and December 31, 2019

0

0

0

0

0

0

0

Common stock, par value $0.0001; 1,600,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 370,102,805 and 336,536,985 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

0

0

0

0

0

0

0

Additional paid-in capital

3,267

2,669

2,618

2,582

2,556

2,538

71

Accumulated other comprehensive (loss) income

-6

1

2

2

0

-1

-1

Retained Earnings (Accumulated Deficit)

-1,620

-1,496

-1,369

-1,246

-1,111

-1,006

-621

Total stockholders’ equity

1,640

1,174

1,251

1,338

1,446

1,530

-551

Total liabilities and stockholders’ equity

2,067

1,589

1,590

1,685

1,806

1,962

1,084